| James F Hatch, MD | |
|
1300 Anne St Nw, Bemidji, MN 56601-5103 | |
| (218) 333-5000 | |
| (218) 333-5360 |
| Full Name | James F Hatch |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine |
| Experience | 50 Years |
| Location | 1300 Anne St Nw, Bemidji, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437177086 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 22610 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sanford Bemidji Medical Center | Bemidji, MN | Hospital |
| Sanford Bagley Medical Center | Bagley, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sanford Health Of Northern Minnesota | 5597725168 | 258 |
News Archive
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it has completed a license amendment with The Dow Chemical Company for a variety of antibodies used in its proprietary surgical oncology system called radioimmunoguided surgery or RIGS®.
According to the Agency for Healthcare Research and Quality, more than 300,000 total hip replacements are performed in the United States each year. The procedure reduces pain and restores mobility. However, for younger, more active patients, an artificial hip has a limited lifetime and usually requires restricted activity.
Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.
In a discovery that could lead to more targeted and effective treatments for certain lung and prostate cancers, researchers at the University of Virginia School of Medicine have identified two new cancer-causing gene mutations - mutations that may be particularly susceptible to cancer-fighting drugs already approved by the federal Food and Drug Administration. One of the gene mutations also may play a key role in early menopause.
In Germany, several national health campaigns promote cancer screening by announcing that only one in five German men gets screened. This is supposed to motivate men to have an examination. But a new study published in Psychological Science, a journal of the Association for Psychological Science, finds that this well-meaning message has the exact opposite effect: it makes men less likely to choose to get screened.
› Verified 1 days ago
| Entity Name | Sanford Health Of Northern Minnesota |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770849697 PECOS PAC ID: 5597725168 Enrollment ID: O20041025000442 |
News Archive
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it has completed a license amendment with The Dow Chemical Company for a variety of antibodies used in its proprietary surgical oncology system called radioimmunoguided surgery or RIGS®.
According to the Agency for Healthcare Research and Quality, more than 300,000 total hip replacements are performed in the United States each year. The procedure reduces pain and restores mobility. However, for younger, more active patients, an artificial hip has a limited lifetime and usually requires restricted activity.
Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.
In a discovery that could lead to more targeted and effective treatments for certain lung and prostate cancers, researchers at the University of Virginia School of Medicine have identified two new cancer-causing gene mutations - mutations that may be particularly susceptible to cancer-fighting drugs already approved by the federal Food and Drug Administration. One of the gene mutations also may play a key role in early menopause.
In Germany, several national health campaigns promote cancer screening by announcing that only one in five German men gets screened. This is supposed to motivate men to have an examination. But a new study published in Psychological Science, a journal of the Association for Psychological Science, finds that this well-meaning message has the exact opposite effect: it makes men less likely to choose to get screened.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| James F Hatch, MD Po Box 5074, Sioux Falls, SD 57117-5074 Ph: () - | James F Hatch, MD 1300 Anne St Nw, Bemidji, MN 56601-5103 Ph: (218) 333-5000 |
News Archive
Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, announced today that it has completed a license amendment with The Dow Chemical Company for a variety of antibodies used in its proprietary surgical oncology system called radioimmunoguided surgery or RIGS®.
According to the Agency for Healthcare Research and Quality, more than 300,000 total hip replacements are performed in the United States each year. The procedure reduces pain and restores mobility. However, for younger, more active patients, an artificial hip has a limited lifetime and usually requires restricted activity.
Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.
In a discovery that could lead to more targeted and effective treatments for certain lung and prostate cancers, researchers at the University of Virginia School of Medicine have identified two new cancer-causing gene mutations - mutations that may be particularly susceptible to cancer-fighting drugs already approved by the federal Food and Drug Administration. One of the gene mutations also may play a key role in early menopause.
In Germany, several national health campaigns promote cancer screening by announcing that only one in five German men gets screened. This is supposed to motivate men to have an examination. But a new study published in Psychological Science, a journal of the Association for Psychological Science, finds that this well-meaning message has the exact opposite effect: it makes men less likely to choose to get screened.
› Verified 1 days ago
Rodney D Will, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1233 34th St Nw, Bemidji, MN 56601 Phone: 218-333-5000 Fax: 218-759-5024 | |
Calvin Tsogmo, Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1300 Anne St Nw, Bemidji, MN 56601 Phone: 218-333-5000 | |
Dr. Mary Susanna Salter, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 514 Beltrami Ave Nw, Bemidji, MN 56601 Phone: 218-766-9281 | |
Dr. Hina Rahman, M.B.,B.S. Internal Medicine Medicare: Medicare Enrolled Practice Location: 1233 34th St Nw, Bemidji, MN 56601 Phone: 218-333-5305 | |
Dr. John D Kolstoe, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1300 Anne St Nw, Bemidji, MN 56601 Phone: 218-333-6000 | |
Daniel Peter Dekrey, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1300 Anne St Nw, Bemidji, MN 56601 Phone: 218-333-5000 | |
Kirstin S Lesage, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1233 34th St Nw, Bemidji, MN 56601 Phone: 218-333-5522 |